Laurus Labs invests Rs 107.8 Cr in KRKA Pharma JV; stake unchanged at 49%

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹2029.00

prior close

₹2025.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.3%-0.2% vs market

Pharmaceuticals peers, median of 172sector-0.6%+0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.6

15m

-0.7

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.3-0.2-0.6+0.1

Next day

+1.5-0.4+1.9-0.7+2.2

+2.0-1.5+3.4-1.9+3.9

-0.8-2.8+2.0-3.5+2.7

-1.3-3.6+2.3-4.4+3.1

-2.9-5.6+2.7-6.1+3.2

+5.6-3.7+9.3-2.9+8.4

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs invested Rs 107.8 crore in KRKA Pharma Private Limited, its joint venture with Slovenia's KRKA d.d., via a rights issue. It subscribed to 10.78 crore equity shares at face value of Rs 10 each. Post-investment, Laurus holds 26.215 crore shares, with its 49% stake unchanged. This follows an earlier investment intimated on April 30, 2026.

Likely market impact

Continued capital infusion into existing JV without altering shareholding. Neutral on ownership; value depends on JV's growth plans.